Expression of ENTPD1/CD39 is protective in a mouse model of biliary fibrosis

被引：0
|
作者：
Feldbruegge, Linda [1 ,3 ]
Mitsuhashi, Shuji [1 ]
Csizmadia, Eva [1 ]
Sun, Xiaofeng [1 ]
Schmelzle, Moritz [2 ]
Robson, Simon C. [1 ]
机构：
[1] BIDMC, Gastroenterol, Boston, MA USA
[2] Charite, Dept Surg, Berlin, Germany
[3] Univ Hosp Leipzig, Dept Surg, Leipzig, Germany
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1394
引用
收藏
页码：892A / 892A
页数：1
相关论文
共 50 条
  • [1] Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis
    Rothweiler, Sonja
    Feldbruegge, Linda
    Jiang, Zhenghui Gordon
    Csizmadia, Eva
    Longhi, Maria Serena
    Vaid, Kahini
    Enjyoji, Keiichi
    Popov, Yury V.
    Robson, Simon C.
    PURINERGIC SIGNALLING, 2019, 15 (03) : 375 - 385
  • [2] Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis
    Sonja Rothweiler
    Linda Feldbrügge
    Zhenghui Gordon Jiang
    Eva Csizmadia
    Maria Serena Longhi
    Kahini Vaid
    Keiichi Enjyoji
    Yury V. Popov
    Simon C. Robson
    Purinergic Signalling, 2019, 15 : 375 - 385
  • [3] The Ectonucleotidase ENTPD1/CD39 Limits Biliary Injury and Fibrosis in Mouse Models of Sclerosing Cholangitis
    Peng, Zhen-Wei
    Rothweiler, Sonja
    Wei, Guangyan
    Ikenaga, Naoki
    Liu, Susan B.
    Sverdlov, Deanna Y.
    Vaid, Kahini A.
    Longhi, Maria Serena
    Kuang, Ming
    Robson, Simon C.
    Popov, Yury V.
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (09) : 957 - 972
  • [4] CD39/ENTPD1 is protective in a model of biliary fibrosis and modulates CD8+T cell gut-homing via α4β7 integrin
    Rothweiler, Sonja
    Peng, Zhen-Wei
    Liu, Susan B.
    Ikenaga, Naoki
    Popov, Yury
    Robson, Simon C.
    HEPATOLOGY, 2015, 62 : 619A - 620A
  • [5] ENTPD1/CD39 is a promising therapeutic target in oncology
    Bastid, J.
    Cottalorda-Regairaz, A.
    Alberici, G.
    Bonnefoy, N.
    Eliaou, J-F
    Bensussan, A.
    ONCOGENE, 2013, 32 (14) : 1743 - 1751
  • [6] ENTPD1/CD39 is a promising therapeutic target in oncology
    J Bastid
    A Cottalorda-Regairaz
    G Alberici
    N Bonnefoy
    J-F Eliaou
    A Bensussan
    Oncogene, 2013, 32 : 1743 - 1751
  • [7] CD39/ENTPD1: At the interface between innate and adaptive immunity
    Robson, Simon C.
    Keiichi, Enjyoji
    Wu, Yan
    Beldi, Guido
    Banz, Yara
    Kunzli, Beat
    Sun, Xiaofeng
    Friedman, David
    Deaglio, Silvia
    Dwyer, Karen
    Strom, Terry
    PURINERGIC SIGNALLING, 2008, 4 : S3 - S3
  • [8] Deletion of Cd39/Entpd1 results in hepatic insulin resistance
    Enjyoji, Keiichi
    Kotani, Ko
    Thukral, Chandrashekar
    Blumel, Benjamin
    Sun, Xiaofeng
    Wu, Yan
    Imai, Masato
    Friedman, David
    Csizmadia, Eva
    Bleibel, Wissam
    Kahn, Barbara B.
    Robson, Simon C.
    DIABETES, 2008, 57 (09) : 2311 - 2320
  • [9] High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
    Zhang, Bin
    Cheng, Bo
    Li, Feng-Sheng
    Ding, Jian-Hua
    Feng, Ying-Ying
    Zhuo, Guang-Zuan
    Wei, Hua-Feng
    Zhao, Ke
    TUMOR BIOLOGY, 2015, 36 (12) : 9411 - 9419
  • [10] CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
    Li, Cuicui
    Zhang, Litian
    Jin, Qiqi
    Jiang, Haoyun
    Wu, Chongyang
    BIOMARKERS IN MEDICINE, 2023, 17 (12) : 563 - 576
12345